Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431260 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02431260: Clinical Trial Phase 1 study, sponsored by Incyte Corporation.
NCT02431260 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02431260, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
Primary Outcome
TEAE is defined as an adverse event reported for the first time or worsening of a pre-existing event after the first dose of study treatment.
Interventions
- DRUG INCB054329 Monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 1 |
Why NCT02431260 stopped before completion
NCT02431260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 1 intervention - of which INCB054329 Monotherapy is the first listed.
NCT02431260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02431260 about?
NCT02431260 is a clinical study titled "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies". This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
What is the current status of trial NCT02431260?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2015-04-14. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02431260?
The interventions under investigation include: INCB054329 Monotherapy (DRUG).
Who is sponsoring clinical trial NCT02431260?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02431260's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI